Comparative preclinical and clinical pharmacokinetics of a Cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol)

Clinical Cancer Research

Volumn 11, Issue 11, 2005, Pages 4136-4143

  Sparreboom, Alex ^a   Scripture, Charity D ^a   Trieu, Vuong ^b   Williams, Paul J ^c   De, Tapas ^b   Yang, Andrew ^b   Beals, Bridget ^b   Figg, William D ^a   Hawkins, Michael ^b   Desai, Neil ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b American BioScience Inc   (United States)

^c UNIVERSITY OF THE PACIFIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREMOPHOR; NANOPARTICLE; PACLITAXEL; TRITIUM;

ADULT; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; FECES; FEMALE; HUMAN; ISOTOPE LABELING; MALE; MICELLE; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RAT; RAT STRAIN; RUSSIAN FEDERATION; SOLID TUMOR;

ADULT; AGED; ALBUMINS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 20344370984     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2291     Document Type: Article

References (26)

1. Wani MC, Taylor HL, Wall ME, et al. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325-7.
2. Adams JD, Flora KP, Goldspiel BR, et al. Taxol: a history of pharmaceutical development and current pharmaceutical concerns. Monogr Natl Cancer Inst 1993;15:141-7.
3. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990;82:1247-59.
4. Taxol® (paclitaxel) injection [package insert]. Princeton (NJ): Bristol-Myers Squibb Co.; 2003 Mar.
5. Gelderblom H, Verweij J, Nooter K, et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37:1590-8.
6. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from Taxol. J Clin Oncol 1990;8:1263-8.
7. Kloover JS, den Bakker MA, Gelderblom H, et al. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer 2004;90:304-5.
8. ten Tije AJ, Verweij J, Loos WJ, et al. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 2003;42:665-85.
9. Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002;8:1038-44.
10. Nyman DW, Campbell KJ, Patrick K, et al. A phase I trial of ABI-007 administered weekly for 3 doses every 4 weeks in patients with advanced non-hematologic malignancies. Presented at: 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans, LA.
11. Nabholtz J-M, Gelmon K, Bontenbal M, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996;14:1858-67.
12. O'Shaughnessy J, Tjulandin S, Davidson N, et al. ABI-007 (Abraxane™), a nanoparticle albumin-bound (nab) paclitaxel demonstrates superior efficacy vs Taxol in MBC: a phase III trial. Presented at: 26th Annual Meeting of the San Antonio Breast Cancer Symposium; 2003 Dec 3-6; San Antonio, TX. Late-breaker Abstract 44.
13. Sparreboom A, van Zuylen L, Brouwer E, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999;59:1454-7.
14. Henningsson A, Karlsson MO, Viganȯ L, et al. Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol 2001;19:4065-73.
15. Henningsson A, Sparreboom A, Sandström M, et al. Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients. Eur J Cancer 2003;39:1105-14.
16. 3H]-paclitaxel in rats: a quantitative autoradiographic study. Cancer Chemother Pharmacol 1995;37:173-8.
17. 3H]Taxol in the Sprague-Dawley rat. Drug Metab Dispos 1994;22:254-8.
18. 1 mice. Cancer Chemother Pharmacol 1994;34:465-71.
19. Sparreboom A, Huizing MT, Boesen JJB, et al. Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human feces. Cancer Chemother Pharmacol 1995;36:299-304.
20. Glantz MJ, Choy H, Kearns CM, et al. Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas. J Clin Oncol 1996;14:600-9.
21. Ellis AG, Webster LK. Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL. Cancer Chemother Pharmacol 1999;43:13-8.
22. Gelderblom H, Verweij J, van Zomeren DM, et al. Influence of Cremophor EL on the bioavailability of intraperitoneal paclitaxel. Clin Cancer Res 2002;8:1237-41.
23. Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995;13:180-90.
24. van den Bongard HJ, Mathot RA, van Tellingen O, et al. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling. Cancer Chemother Pharmacol 2002;50:16-24.
25. Baker RJ, Kozoll DD, Meyer KA. The use of surface area as a basis for establishing normal blood volume. Surg Gynecol Obstet 1957;104:183-9.
26. Smorenburg CH, Sparreboom A, Bontenbal M, et al. Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel. J Clin Oncol 2003;21:197-202.